Invention Grant
US08637664B2 Alkyl 4- [4- (5-oxo-2,3,5, 11a-tetrahydo-5H-pyrrolo [2, 1-c] [1,4] benzodiazepine-8-yloxy)-butyrylamino]-1H-pyrrole-2-carboxylate derivatives and related compounds for the treatment of a proliferative disease
有权
4- [4-(5-氧代-2,3,5,11a-四氢-5H-吡咯并[2,1-c] [1,4]苯并二氮杂-8-基氧基) - 丁酰基氨基] -1H-吡咯 - 2-羧酸酯衍生物和相关化合物,用于治疗增殖性疾病
- Patent Title: Alkyl 4- [4- (5-oxo-2,3,5, 11a-tetrahydo-5H-pyrrolo [2, 1-c] [1,4] benzodiazepine-8-yloxy)-butyrylamino]-1H-pyrrole-2-carboxylate derivatives and related compounds for the treatment of a proliferative disease
- Patent Title (中): 4- [4-(5-氧代-2,3,5,11a-四氢-5H-吡咯并[2,1-c] [1,4]苯并二氮杂-8-基氧基) - 丁酰基氨基] -1H-吡咯 - 2-羧酸酯衍生物和相关化合物,用于治疗增殖性疾病
-
Application No.: US12089459Application Date: 2006-10-05
-
Publication No.: US08637664B2Publication Date: 2014-01-28
- Inventor: Philip Wilson Howard , David Edwin Thurston , Geoffrey Wells
- Applicant: Philip Wilson Howard , David Edwin Thurston , Geoffrey Wells
- Applicant Address: CH St-Legier-la Chiesaz
- Assignee: Spirogen SARL
- Current Assignee: Spirogen SARL
- Current Assignee Address: CH St-Legier-la Chiesaz
- Agency: Michael Best & Friedrich LLP
- International Application: PCT/GB2006/003718 WO 20061005
- International Announcement: WO2007/039752 WO 20070412
- Main IPC: C07D223/10
- IPC: C07D223/10 ; A01N43/62 ; A61K31/55
![Alkyl 4- [4- (5-oxo-2,3,5, 11a-tetrahydo-5H-pyrrolo [2, 1-c] [1,4] benzodiazepine-8-yloxy)-butyrylamino]-1H-pyrrole-2-carboxylate derivatives and related compounds for the treatment of a proliferative disease](/abs-image/US/2014/01/28/US08637664B2/abs.jpg.150x150.jpg)
Abstract:
A compound of formula (I); or a salt or solvate thereof, wherein: the dotted line indicates the optional presence of a double bond between C2 and C3; R2 is selected from —H, —OH, =0, ═CH2, —CN, —R, OR, halo, ═CH—R, O—SO2—R, CO2R and COR; R7 is selected from H, R, OH, OR, SH, SR, NH2, NHR, NRR′, nitro, Me3Sn and halo, where R and R′ are independently selected from optionally substituted C1-7 alkyl, C3-20 heterocyclyl and C5-20 aryl groups; R10 and R11 either together form a double bond, or are selected from H and YRY, where Y is selected from O, S and NH and R is H or C1-7 alkyl or H and SOxM, where x is 2 or 3 and M is a monovalent pharmaceutically acceptable cation; each X is independently a heteroarylene group; n is from 1 to 6; and RE is C1-4 alkyl. The compound is useful for the treatment of proliferative diseases.
Public/Granted literature
Information query